By continuing, you agree to the Terms of Service.
This website uses cookies to enhance your browsing experience. Learn More.
Essential Cookies
Optional Cookies
Login
Logo for company OptiBiotix Health Plc

OptiBiotix Health Plc (OPTI.L)

LSE Currency in GBP
£12.00
-£0.23
-1.90%
Last Update: 16 Jul 2025, 15:35
£12.40M
Market Cap
0.00
P/E Ratio (TTM)
Forward Dividend Yield
£10.00 - £35.00
52 Week Range

OPTI.L Stock Price Chart

Explore OptiBiotix Health Plc interactive price chart. Choose custom timeframes to analyze OPTI.L price movements and trends.

There is nothing to show.

OPTI.L Company Profile

Discover essential business fundamentals and corporate details for OptiBiotix Health Plc (OPTI.L) to support your stock research and investment decisions.

Sector

Healthcare

Industry

Biotechnology

IPO Date

9 Sept 2011

Employees

10.00

CEO

Stephen Patrick O'Hara

Description

OptiBiotix Health Plc, a life sciences company, engages in the research and development of microbiome modulators primarily in the United Kingdom. The company identifies and develops microbial strains, compounds, and formulations for use in food ingredients, supplements, and active compounds that impacts human physiology deriving potential health benefits. Its products include Slimbiome, a natural ingredient, which offers a healthy and hunger-free weight management system; SlimBiome Medical, a natural supplement for weight management; CholBiome, a food supplement for maintaining healthy levels of cholesterol; Lactobacillus plantarum LPLDL, a probiotic that aids elements of cardiovascular and wellbeing; LPGOS, a galactooligosaccharid that is used in food products and applications, which helps in reducing cardiovascular risk factors and enhancing health; WellBiome, a functional fibre and mineral blend that supports health & wellbeing by promoting the diversity of the gut microbiome; and Sweetbiotix, a sweetener for use in food and beverages. The company's products prevents and manages chronic lifestyle diseases, including obesity, hypercholesterolemia and lipid profiles, and diabetes. OptiBiotix Health Plc was founded in 2012 and is headquartered in York, the United Kingdom.

OPTI.L Financial Timeline

Browse a chronological timeline of OptiBiotix Health Plc corporate events including earnings releases, dividend announcements, and stock splits.

Upcoming earnings on 25 Sept 2025

Earnings released on 26 Jun 2025

Earnings released on 27 Sept 2024

EPS came in at -£0.03, while revenue for the quarter reached £276.00K.

Earnings released on 28 Jun 2024

EPS came in at -£0.00, while revenue for the quarter reached £293.00K.

Earnings released on 27 Sept 2023

EPS came in at -£0.02, while revenue for the quarter reached £351.00K.

Earnings released on 28 Jun 2023

EPS came in at -£0.12, while revenue for the quarter reached £338.10K.

Earnings released on 28 Sept 2022

EPS came in at £0.16, while revenue for the quarter reached £118.90K.

Earnings released on 31 Dec 2021

EPS came in at -£0.09, while revenue for the quarter reached £1.14M.

Earnings released on 30 Jun 2021

EPS came in at £0.16, while revenue for the quarter reached £1.08M, beating expectations by +0.19%.

Earnings released on 31 Dec 2020

EPS came in at £0.07, while revenue for the quarter reached £778.43K.

OPTI.L Stock Performance

Access detailed OPTI.L performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.

There is nothing to show.
OPTI.L
Company Name
Exchange
Market Currency
Report Currency
Price
Price Change
Percentage Change
50-Day Average Price
200-Day Average Price
Trading Volume
Market Capitalization
OPTI.L
2025
2024
2023
2022
2021
Revenue
Gross Profit
Earnings Before Interest and Taxes (EBIT)
Net Income
Total Current Assets
Total Assets
Total Liabilities
Net Debt
Total Equity
Cash Flow from Operating
Cash Flow from Investing
Cash Flow from Financing
Free Cash Flow

Explore Related Stocks

Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.

Discover More